Engineered Monocytes for Antigen-Specific Tolerance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for autoimmune diseases often require lifelong immunosuppression and rely on non-specific inhibition of immune inflammatory activity, lacking antigen-specificity, and face challenges in scaling up particle-based therapeutics due to issues with physicochemical properties and antigen release.
Innovation Solution
A population of human monocytes engineered to express recombinant nucleic acids encoding human autoimmune antigens, which are then introduced into apoptotic vesicles, allowing for antigen-specific immune tolerance induction without high initial immunosuppressive doses, using RNA vectors with stabilizing sequences and electroporation for delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If global immunosuppressants or immunomodulators are used to treat autoimmune diseases, then immune inflammatory activity is inhibited, but antigen-specificity is lost and lifelong treatment is required
Solution Approach 1:
The patent applies local quality by engineering monocytes to express specific autoimmune antigens on their surface, creating a localized antigen-specific therapeutic effect. The monocytes are modified to present only the specific autoantigen of interest (e.g., myelin oligodendrocyte glycoprotein for multiple sclerosis) rather than providing global immunosuppression, thereby achieving antigen-specific tolerance while preserving other immune functions.
Solution Approach 2:
The patent uses engineered monocytes as intermediary cells that mediate between the specific autoantigen and the patient's immune system. These monocytes present the autoantigen in a tolerogenic manner, acting as a bridge to induce antigen-specific tolerance without requiring direct administration of immunosuppressive drugs. The monocytes serve as living carriers that deliver the tolerogenic signal specifically to T cells reactive to the target autoantigen.
2Quantity of substance
If particle-based therapeutics are used to deliver antigens, then antigen delivery is achieved, but scaling up is difficult due to physicochemical property control issues
Solution Approach 1:
The patent applies self-service by using living monocytes as self-sustaining antigen delivery vehicles. Rather than relying on artificial particles that require precise manufacturing control, the engineered monocytes naturally express and present the autoantigen on their surface through endogenous protein synthesis. The cells self-regulate antigen expression levels and can be expanded in standard cell culture conditions, greatly simplifying manufacturing and scale-up compared to particle-based systems.
Solution Approach 2:
The patent changes the fundamental parameter of antigen delivery from inert particles to living cells. This parameter change allows for dynamic regulation of antigen expression and presentation, while also enabling easier manufacturing through standard cell culture techniques. The monocytes can be expanded in large numbers under controlled conditions, and their antigen expression can be modulated by adjusting culture conditions or genetic engineering parameters, providing flexibility that particle systems lack.
3Reliability
If high initial doses of immunosuppressive drugs are administered, then immune tolerance is induced, but side effects increase and long-term use is required
Solution Approach 1:
The patent applies local quality by directing immunosuppressive effects specifically to T cells reactive to the target autoantigen. The engineered monocytes present the autoantigen in a tolerogenic context, inducing antigen-specific regulatory T cells or anergic T cells only against the specific autoantigen. This localized immunomodulation avoids the broad immunosuppression and associated side effects of high-dose conventional immunosuppressive drugs.
Solution Approach 2:
The patent uses short-lived engineered monocytes as disposable tolerogenic carriers. These monocytes are administered to induce antigen-specific tolerance and then naturally die off after fulfilling their function, eliminating the need for lifelong immunosuppressive drug therapy. The transient nature of the cell therapy provides a time-limited intervention that achieves the desired immune modulation without long-term drug exposure and its associated side effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables efficient long-term immune tolerance with reduced immunosuppressive drug use, effectively targeting specific autoimmune antigens and promoting tolerogenic responses, thereby treating autoimmune diseases with improved specificity and efficacy.
Implementation Method 1
A population of human monocytes engineered to express recombinant nucleic acids encoding human autoimmune antigens
Implementation Method 2
using RNA vectors with stabilizing sequences and electroporation for delivery
Data Source
AI summary
Methods and compositions for treating autoimmune diseases and conditions using engineered myeloid cells.